Swiss cost containment package 2 makes important corrections

Interpharma, the association of research-based pharmaceutical companies in Switzerland, on Friday welcomed decisions by the National Council's Health Committee on Cost Containment Package 2.

The committee has made certain corrections and is determined not to further weaken patients' increasingly poor access to innovative medicines. However, further improvements are needed in the plenary session.

The National Council's Health Committee (SGK-N) has once again dealt with the Federal Council's second cost-containment package (KP2). After both the National Council and the Council of States had recently failed several times to improve access to medicines for all patients in Switzerland, the SGK-N has made improvements in certain areas. This is all the more important because various current studies show that the supply of innovative medicines in Switzerland is increasingly under threat.